Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract: A processing system includes a processor configured to perform an annealing process to individually control, depending on time, each contribution of a cost function, a transverse field function, and an orthogonal field function, and perform an optimization process to sequentially determine an optimal value of the contribution of the orthogonal field function based on a final state of the annealing process. The processor is configured to extract the qubit that optimizes an evaluation indicator for the final state of the annealing process in which an intensity parameter for maximizing the orthogonal field function is varied, based on a gradient caused by the variation. The processor is configured to determine the intensity parameter that gives the optimal value for the extracted qubit based on the gradient, and output an optimal solution of the combinatorial optimization problem by mapping a set of the intensity parameters determined for each of the qubits.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

Abstract: An information processing device: acquires data and prepares a data set with the acquired data; generates a regression model using the data set; calculates an optimum solution from the generated regression model; repetitively acquires the data based on the calculated optimum solution and updating the data set; and repetitively generates the regression model using the updated data set. The acquiring of data and the preparing of data set are executed based on a different criterion in response to a satisfaction of a predetermined condition, and the generating of regression model is executed using the data set prepared based on the different criterion.

Abstract: In an information processing apparatus, a selection unit selects, from a plurality of nodes that constitute a trained model, one or more nodes that are to be dropped out from the trained model as one or more dropout nodes. The trained model is configured to output, in response to input information being input thereto, output information. An identifier is configured to identify, in the plurality of nodes that constitute the trained model, one or more relatively coadapted nodes in accordance with an appropriateness of the trained model from which the one or more dropout nodes have been dropped out.

Abstract: By an information process device, a data decomposition method, or a data decomposition program stored in a computer-readable non-transitory storage medium, model data including multiple values is approximated by approximate data including a combination of basis data and coefficient data. A basis data candidate that constitutes the approximate data is selected. An approximate data candidate and an evaluation metric that evaluates the approximate data candidate are calculated. A regression model representing a relationship between the evaluation metric and the basis data candidate is generated. The selection, calculation, and generation are executed at least once. The coefficient data is calculated. The basis data candidate is selected to cause the regression model to more accurately predict the evaluation metric.

Abstract: An apparatus has a first function of selecting, from individual prediction models, candidate models, a second function of training the candidate models using a training dataset, a third function of applying a test dataset to a candidate integrated model to calculate an evaluation metric, and a fourth function of generating a regression expression between the evaluation metric and the candidate combination. A controller repeats a sequence of the first to fourth functions while the first function selects new individual models for each sequence until a termination condition is satisfied. The regression expression generated with an additional value of the evaluation metric from the new candidate combination for each sequence has a higher prediction accuracy on average as the number of the repeated sequences increases. A determiner determines an integrated model based on the candidate integrated models and values of the evaluation metric after the termination condition is satisfied.

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

Abstract: Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is in need of a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.

Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.

Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.

Abstract: An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using a decrease in gene expression level as an index.

Abstract: An object of the present invention is to provide a method, a probe, a primer, an antibody, a reagent, and a kit for assaying an action of a pladienolide derivative to a living subject. According to the present invention, there is provided a method for assaying an action of the pladienolide derivative using splicing defect as an index.

Abstract: A semiconductor device comprises varactor regions Va and transistor regions Tr. An active region for a varactor is formed with a substrate contact impurity diffusion region obtained by doping an N well region with N-type impurity at a relatively high concentration. However, any extension region (or LDD region) as in a varactor of a known semiconductor device is not formed in the active region for a varactor. On the other hand, parts of a P well region located to both sides of the polysilicon gate electrode in the transistor region Tr are formed with high-concentration source/drain regions and extension regions. Therefore, the extendable range of a depletion layer is kept wide to extend the capacitance variable range of the varactor.

Abstract: A substrate 11 consists of a semiconductor layer 12 as an element formation region and an STI 13 as an isolation region. A gate dielectric 15 is provided on the semiconductor layer 12, and a gate electrode 14 is provided to extend from the top of the gate dielectric 15 to the top of the STI 13. A sidewall 30 for covering the sides of the gate electrode 14 is provided to extend across the top of the semiconductor layer 12 to the tops of regions of the STI 13 adjacent to the outer edges of the semiconductor layer 12. The sidewall 30 is employed as an ion implantation mask for forming high-concentration impurity diffusion layers 16 each serving as a source/drain region.